These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22242194)

  • 1. Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
    Nishijima T; Gatanaga H; Komatsu H; Tsukada K; Shimbo T; Aoki T; Watanabe K; Kinai E; Honda H; Tanuma J; Yazaki H; Honda M; Teruya K; Kikuchi Y; Oka S
    PLoS One; 2012; 7(1):e29977. PubMed ID: 22242194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.
    Nishijima T; Komatsu H; Gatanaga H; Aoki T; Watanabe K; Kinai E; Honda H; Tanuma J; Yazaki H; Tsukada K; Honda M; Teruya K; Kikuchi Y; Oka S
    PLoS One; 2011; 6(7):e22661. PubMed ID: 21799928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
    J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
    Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
    AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
    Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
    Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
    Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
    Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
    Stöhr W; Reid A; Walker AS; Ssali F; Munderi P; Mambule I; Kityo C; Grosskurth H; Gilks CF; Gibb DM; Hakim J;
    Antivir Ther; 2011; 16(7):1011-20. PubMed ID: 22024517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.
    Chaisiri K; Bowonwatanuwong C; Kasettratat N; Kiertiburanakul S
    Curr HIV Res; 2010 Oct; 8(7):504-9. PubMed ID: 21073439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
    Horberg M; Tang B; Towner W; Silverberg M; Bersoff-Matcha S; Hurley L; Chang J; Blank J; Quesenberry C; Klein D
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):62-9. PubMed ID: 19838127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
    Post FA; Moyle GJ; Stellbrink HJ; Domingo P; Podzamczer D; Fisher M; Norden AG; Cavassini M; Rieger A; Khuong-Josses MA; Branco T; Pearce HC; Givens N; Vavro C; Lim ML
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):49-57. PubMed ID: 20431394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.
    Padilla S; Masiá M; García N; Jarrin I; Tormo C; Gutiérrez F
    BMC Infect Dis; 2011 Feb; 11():40. PubMed ID: 21294867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
    Andrade-Fuentes K; Mata-Marín JA; López-De León JI; Manjarrez-Téllez B; Ramírez JL; Gaytan-Martínez J
    AIDS Patient Care STDS; 2015 Apr; 29(4):181-5. PubMed ID: 25101526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
    Rasch MG; Engsig FN; Feldt-Rasmussen B; Kirk O; Kronborg G; Pedersen C; Gerstoft J; Obel N
    Scand J Infect Dis; 2012 Sep; 44(9):689-96. PubMed ID: 22680981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.
    Choi AI; Vittinghoff E; Deeks SG; Weekley CC; Li Y; Shlipak MG
    AIDS; 2011 Jun; 25(10):1289-98. PubMed ID: 21516027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
    N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of gender and anchor drugs on TDF renal toxicity.
    Quiros-Roldan E; Amadasi S; Paraninfo G; Izzo I; Allegri R; Motta D; Gatti F; Cristini G; Carosi G; Mendeni M; Torti C
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):e11-2. PubMed ID: 20859083
    [No Abstract]   [Full Text] [Related]  

  • 19. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
    Negredo E; Domingo P; Pérez-Álvarez N; Gutiérrez M; Mateo G; Puig J; Escrig R; Echeverría P; Bonjoch A; Clotet B
    J Antimicrob Chemother; 2014 Dec; 69(12):3368-71. PubMed ID: 25125679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.